You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
信達生物(01801.HK)與和黃醫藥拓展合作 開展藥品實體瘤聯合治療臨床評估
阿思達克 10-10 16:24

信達生物(01801.HK)公布,與和黃醫藥進一步拓展雙方的全球臨床合作,共同評估信達生物的重組全人源抗PD-1單克隆抗體達伯舒(信迪利單抗注射液),與和黃醫藥的索凡替尼(一種新型血管內皮生長因子受體及成纖維細胞生長因子受體1抑製劑,同時抑制集落刺激因子-1受體)聯合治療晚期實體瘤患者的安全性和有效性。

兩家公司是次合作是在現有的全球合作協議,即共同評估信迪利單抗與和黃醫藥的高選擇性血管內皮生長因子受體抑製劑基礎上進一步擴展合作範圍。

信達生物與和黃醫藥進一步拓展全球臨床合作可讓雙方共同就達伯舒與索凡替尼針對實體瘤中未滿足的臨床需求進行共同探索和開發。新組合的臨床研究將在美國和中國進行。達伯舒和索凡替尼的聯合療法有望通過同時針對腫瘤微環境中的多種細胞類型和信號傳導途徑而帶來協同的抗癌作用。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account